TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
17
03
2021
received:
14
01
2021
accepted:
29
03
2021
pubmed:
1
5
2021
medline:
13
1
2022
entrez:
30
4
2021
Statut:
ppublish
Résumé
Increasing understanding of cytokines as major drivers of immune-mediated diseases has revolutionized targeted treatments for these conditions. As the pathogenesis of autoimmune conditions is mediated by a complex interplay of various cytokines, Janus kinase (JAK) inhibitors have been of particular interest due to their ability to target multiple cytokines simultaneously. However, due to safety concerns with first generation JAK inhibitors, most notably from JAK2 and JAK3 inhibition, interest has shifted to more selective inhibition of TYK2. Three key TYK2 inhibitors that have advanced furthest in clinical trials for treatment of dermatologic autoimmune conditions are deucravacitinib (BMS-986165), brepocitinib (PF-06700841), and PF-06826647. This review outlines the current understanding of the efficacy and safety of these three TYK2 inhibitors from completed phase I and II studies and summarizes studies currently in progress for dermatologic conditions.
Substances chimiques
Cytokines
0
Janus Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-147Informations de copyright
© 2021 the International Society of Dermatology.
Références
O'Shea JJ, Gadina M. Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol 2019; 15: 74. https://doi.org/10.1038/s41584-018-0155-9
Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J 2014; 462: 1-13. https://doi.org/10.1042/BJ20140712
T. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019; 33: 15-32. https://doi.org/10.1007/s40259-019-00333-w
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery 2017; 16: 843-862.
Gündüz Ö. JAK/STAT pathway modulation: does it work in dermatology? Dermatol Ther 2019; 32: https://doi.org/10.1111/dth.12903
Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatol Treatment. 2019; 30: 648-658. https://doi.org/10.1080/09546634.2018.1546043
Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 2017; 15: 23. https://doi.org/10.1186/s12964-017-0177-y
Crowley EL, Fine SC, Katipunan KK, Gooderham MJ. The use of Janus kinase inhibitors in alopecia areata: a review of the literature. J Cutan Med Surg 2019; 23: 289-297. https://doi.org/10.1177/1203475418824079
van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519. https://doi.org/10.1056/NEJMoa1112072
Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. JAMA Oncol. 2018; 4: 652-https://doi.org/10.1001/jamaoncol.2017.5818
Mascarenhas J, Hoffman R, Talpaz M, et al. Results of the persist-2 Phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl. Blood 2016; 128: LBA-5. https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5
Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65-68. https://doi.org/10.1038/377065a0
Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, NJ). 2016; 68: 46-55. https://doi.org/10.1002/art.39473
Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon αβ signaling pathway. Cell 1992; 70: 313-322. https://doi.org/10.1016/0092-8674(92)90105-L
Rodig SJ, Meraz MA, White JMichael, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKS in cytokine-induced biologic responses. Cell 1998; 93: 373-383. https://doi.org/10.1016/s0092-8674(00)81166-6
Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitivehematopoiesis. Cell 1998; 93: 397-409. https://doi.org/10.1016/S0092-8674(00)81168-X
Parganas E, Wang D, Stravopodis D, et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-395. https://doi.org/10.1016/s0092-8674(00)81167-8
Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13: 549-560.
Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13: 561-571.
Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100: 11594-11599. https://doi.org/10.1073/pnas.1930781100
Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25: 745-755. https://doi.org/10.1016/j.immuni.2006.09.009
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: https://doi.org/10.3390/ijms20061475
Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clinic Rev Allerg Immunol 2018; 54: 102-113. https://doi.org/10.1007/s12016-018-8668-1
Blauvelt A. Dual inhibition of IL-12/IL-23 and selective inhibition of IL-23 in psoriasis. In: Yamauchi PS, ed. Biologic and Systemic Agents in Dermatology. Springer International Publishing, 2018:123-131. https://doi.org/10.1007/978-3-319-66884-0_14
Lebwohl M, Langley RG, Zhu Y, et al. Use of dose-exposure-response relationships in Phase 2 and phase 3 guselkumab studies to optimize dose selection in psoriasis. J European Academy Dermatol Venereol 2019; 33: 2082-2086. https://doi.org/10.1111/jdv.15668
Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet 2017; 390: 276-288. https://doi.org/10.1016/S0140-6736(17)31279-5
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 2018; 392: 650-661. https://doi.org/10.1016/S0140-6736(18)31713-6
Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013; 191: 2205-2216. https://doi.org/10.4049/jimmunol.1202859
Benhadou F, Mintoff D, del Marmol V. Psoriasis: keratinocytes or immune cells - which is the trigger? DRM 2019; 235: 91-100. https://doi.org/10.1159/000495291
Strange A, Capon F, Spencer CC, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985-990. https://doi.org/10.1038/ng.694
Malik K, Guttman-Yassky E. Cytokine targeted therapeutics for alopecia areata: lessons from atopic dermatitis and other inflammatory skin diseases. J Investigative Dermatology Symposium Proceedings 2018; 19: S62-S64. https://doi.org/10.1016/j.jisp.2017.10.005
Trüeb RM, Dias MFRG. Alopecia areata: a comprehensive review of pathogenesis and management. Clinic Rev Allerg Immunol 2018; 54: 68-87. https://doi.org/10.1007/s12016-017-8620-9
Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc 2013; 16: S25-27. https://doi.org/10.1038/jidsymp.2013.7
Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol 2018; 179: 1033-1048. https://doi.org/10.1111/bjd.16808
Wang F-P, Tang X-J, Wei C-Q, Xu L-R, Mao H, Luo F-M. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2018; 90: 190-198. https://doi.org/10.1016/j.jdermsci.2018.01.016
Anzai A, Wang EHC, Lee EY, Aoki V, Christiano AM. Pathomechanisms of immune-mediated alopecia. Int Immunol 2019; 31: 439-447. https://doi.org/10.1093/intimm/dxz039
He X, Chen X, Zhang H, Xie T, Ye X-Y. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018). Expert Opin Ther Pat 2019; 29: 137-149. https://doi.org/10.1080/13543776.2019.1567713
Moslin RM, Weinstein DS, Wrobleski ST, et al. Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses. Published online November 29, 2016. Accessed July 29, 2019. https://patents.google.com/patent/US9505748B2/en
Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 2018; 379: 1313-1321. https://doi.org/10.1056/NEJMoa1806382
An Investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03624127
An investigational study to evaluate experimental medication bms-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03611751
Bristol-Myers Squibb. A multi-center, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of BMS-986165 in subjects with moderate-to-severe plaque psoriasis. clinicaltrials.gov; 2020. Accessed May 17, 2020. https://clinicaltrials.gov/ct2/show/NCT04167462
An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03624127
An investigational study to evaluate BMS-986165 in patients with systemic lupus erythematosus - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03252587
Dose ranging study to assess efficacy, safety and tolerability of PF-06700841 topical cream in psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03850483
A phase 2b Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in active non-segmental vitiligo subjects - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03715829
A dose-ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus (SLE) - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03845517
Dose ranging study to assess efficacy, safety, tolerability and pharmacokinetics of PF-06700841 topical cream in participants with mild or moderate atopic dermatitis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03903822
Pfizer. A phase 2a, multicenter, randomized, double-blind, placebo-controlled, 16-week study evaluating the safety and efficacy of Pf-06650833, Pf-06700841, and Pf-06826647 in adults with moderate to severe hidradenitis suppurativa. Published May 5, 2020. Accessed May 17, 2020. https://clinicaltrials.gov/ct2/show/NCT04092452
Brown MF, Dermenci A, Fensome A, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. Published online August 24, 2017. Accessed July 29, 2019. https://patents.google.com/patent/US20170240552A1/en?oq=+US20170240552
A study to evaluate safety and efficacy of PF-06826647 for moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03895372
Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02931838
Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02974868
Bernardis E, Castelo-Soccio L. Quantifying alopecia areata via texture analysis to automate the SALT score computation. J Investigative Dermatol Symposium Proceedings 2018; 19: S34-S40. https://doi.org/10.1016/j.jisp.2017.10.010
Pfizer presents positive phase 2 data in alopecia areata during late-breaker session at the 27th European Academy of Dermatology and Venereology EADV Congress. Health & Medicine Week. 2018: 153.
PF-06651600 for the treatment of alopecia areata - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03732807
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis - Full Text View - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02969018
A Safety, Tolerability, pharmacokinetics and pharmacodynamics study of pf-06700841, with bioavailability/food effect investigation - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02310750
Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clinical Pharmacol 2018; 58: 434-447. https://doi.org/10.1002/jcph.1046
Lin TE, HuangFu W-C, Chao M-W, et al. A novel selective JAK2 inhibitor identified using pharmacological interactions. Front Pharmacol 2018; 9: https://doi.org/10.3389/fphar.2018.01379
Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017; 389: 266-275. https://doi.org/10.1016/S0140-6736(16)32537-5
Singh JA. Filgotinib, a JAK1 Inhibitor, for treatment-resistant rheumatoid arthritis. JAMA 2019; 322: 309-311. https://doi.org/10.1001/jama.2019.9056
Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391: 2503-2512. https://doi.org/10.1016/S0140-6736(18)31115-2
Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018; 179: 54-62. https://doi.org/10.1111/bjd.16004
O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161-170. https://doi.org/10.1056/NEJMra1202117
Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 2019; 58: 953-962. https://doi.org/10.1093/rheumatology/key339
Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from 2 pivotal, phase 3, randomized, double-blinded, placebo-controlled studies. Oral Presentation; 2020.
Bissonnette R, Luchi M, Fidelus-Gort R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatol Treatment 2016; 27: 332-338. https://doi.org/10.3109/09546634.2015.1115819
Kahl L, Patel J, Layton M, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus 2016; 25: 1420-1430. https://doi.org/10.1177/0961203316640910
Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet 2020; 396: 255-266. https://doi.org/10.1016/S0140-6736(20)30732-7